通过独立于的eNOS抑制抑制勃起功能
Xiaozhi Cheng1, Yunbei Xiao2, Di Qiu3
1Department of Andrology and Sexual Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China; Department of Neurosurgery, People's Hospital of Gaozhou, Maoming, Guangdong 525200, China.
Toxicology and applied pharmacology
|August 23, 2025
概括
通过抑制阴茎组织中的PI3K-Akt-eNOS通路,高血清素直接导致正常勃功能障碍 (ED). 这一发现表明ED患者的新治疗点.
科学领域:
- 内分泌学
- 尿道病学
- 分子生物学
背景情况:
- 勃起功能障碍 (ED) 在患有前素分泌瘤 (前素瘤) 的男性中很常见.
- 在正常丸激素的前乳腺瘤患者中,ED的机制尚不清楚.
- 这项研究调查了益生菌对勃起功能的直接影响.
研究的目的:
- 为了确定是否高血清素直接损害勃起功能独立于.
- 确定涉及到益生菌诱导ED的分子途径.
- 探索潜在的治疗点在前乳腺瘤患者.
主要方法:
- 对患有下垂体瘤和正常的男性进行临床数据分析.
- 使用乙乙醇诱导前乳腺瘤大鼠模型.
- 评估勃起功能,水平和阴茎组织分子通路 (PI3K-Akt-eNOS).
- 在实验室中使用培养的老鼠洞体内皮细胞.
主要成果:
- 在正常丸激素的患者中,高血清素与勃起功能有负相关性.
- 在没有影响水平的情况下诱导ED的老鼠高血糖.
- 布罗莫克里普丁治疗恢复了勃起功能,并改善了阴茎的eNOS表达.
- 在阴茎组织中抑制PI3K-Akt-eNOS信号通路.
- 在培养的洞体内皮细胞中,Prolactin降低了eNOS的表达.
结论:
- 通过抑制PI3K-Akt-eNOS通路而直接损害勃起功能,独立于.
- 这为具有正常丸激素的前乳腺瘤患者提供了ED的分子基础.
- 针对PI3K-Akt-eNOS途径可能为这一群体提供新的治疗策略.
- 对于具有正常水平的乳腺瘤患者,建议对ED进行评估.
相关概念视频
01:26Testosterone: Functions and Regulation
1.0K
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
1.0K
01:29Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
610
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
610
01:28Nitric Oxide Signaling Pathway
5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
01:25Adrenergic Agonists: Indirect-Acting Agents
1.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.8K